235 related articles for article (PubMed ID: 2529543)
1. Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Gros C; Souque A; Schwartz JC; Duchier J; Cournot A; Baumer P; Lecomte JM
Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7580-4. PubMed ID: 2529543
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans.
Lecomte JM; Baumer P; Lim C; Duchier J; Cournot A; Dussaule JC; Ardaillou R; Gros C; Chaignon B; Souque A
Eur J Pharmacol; 1990 Apr; 179(1-2):65-73. PubMed ID: 2163851
[TBL] [Abstract][Full Text] [Related]
3. Diuretic and natriuretic responses in rats treated with enkephalinase inhibitors.
Bralet J; Mossiat C; Lecomte JM; Charpentier S; Gros C; Schwartz JC
Eur J Pharmacol; 1990 Apr; 179(1-2):57-64. PubMed ID: 2142087
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of atrial natriuretic factor in mice in vivo: crucial role of enkephalinase (EC 3.4.24.11).
Gros C; Souque A; Schwartz JC
Eur J Pharmacol; 1990 Apr; 179(1-2):45-56. PubMed ID: 2142086
[TBL] [Abstract][Full Text] [Related]
5. Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications.
Schwartz JC; Gros C; Lecomte JM; Bralet J
Life Sci; 1990; 47(15):1279-97. PubMed ID: 2146457
[TBL] [Abstract][Full Text] [Related]
6. Thiorphan-induced natriuresis in volume-expanded rats: roles of endogenous atrial natriuretic factor and kinins.
Bralet J; Mossiat C; Gros C; Schwartz JC
J Pharmacol Exp Ther; 1991 Sep; 258(3):807-11. PubMed ID: 1653839
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of enkephalinase inhibition in the living mouse, using [3H]acetorphan as a probe.
De la Baume S; Brion F; Dam Trung Tuong M; Schwartz JC
J Pharmacol Exp Ther; 1988 Nov; 247(2):653-60. PubMed ID: 3183961
[TBL] [Abstract][Full Text] [Related]
8. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.
Gros C; Noël N; Souque A; Schwartz JC; Danvy D; Plaquevent JC; Duhamel L; Duhamel P; Lecomte JM; Bralet J
Proc Natl Acad Sci U S A; 1991 May; 88(10):4210-4. PubMed ID: 1851998
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure.
Northridge DB; Jardine AG; Findlay IN; Archibald M; Dilly SG; Dargie HJ
Am J Hypertens; 1990 Sep; 3(9):682-7. PubMed ID: 2145874
[TBL] [Abstract][Full Text] [Related]
10. [Effect of sinorphan, an endopeptidase inhibitor on severe congestive cardiac insufficiency].
Varin J; Duboc D; Weber S; Fouchard J; Schwartz JC; Muffat-Joly M; Guérin F
Arch Mal Coeur Vaiss; 1991 Oct; 84(10):1465-71. PubMed ID: 1662033
[TBL] [Abstract][Full Text] [Related]
11. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites.
Dussaule JC; Grangé JD; Wolf JP; Lecomte JM; Gros C; Schwartz JC; Bodin F; Ardaillou R
J Clin Endocrinol Metab; 1991 Mar; 72(3):653-9. PubMed ID: 1847706
[TBL] [Abstract][Full Text] [Related]
12. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure.
Cavero PG; Margulies KB; Winaver J; Seymour AA; Delaney NG; Burnett JC
Circulation; 1990 Jul; 82(1):196-201. PubMed ID: 2142023
[TBL] [Abstract][Full Text] [Related]
13. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
14. EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide.
Richards AM; Wittert G; Espiner EA; Yandle TG; Frampton C; Ikram H
J Clin Endocrinol Metab; 1991 Jun; 72(6):1317-22. PubMed ID: 1827451
[TBL] [Abstract][Full Text] [Related]
15. Renal tubular sensitivity to atrial natriuretic factor in essential hypertension.
Janssen WM; de Zeeuw D; van der Hem GK; de Jong PE
J Hypertens; 1994 Apr; 12(4):439-47. PubMed ID: 8064168
[TBL] [Abstract][Full Text] [Related]
16. The role of neutral endopeptidase in dogs with evolving congestive heart failure.
Margulies KB; Barclay PL; Burnett JC
Circulation; 1995 Apr; 91(7):2036-42. PubMed ID: 7895362
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats.
Scott JM; Barclay PL; Shepperson NB
Eur J Pharmacol; 1993 Sep; 242(1):91-7. PubMed ID: 8223941
[TBL] [Abstract][Full Text] [Related]
18. Degradation of atrial natriuretic factor in mouse blood in vitro and in vivo: role of enkephalinase (EC 3.4.24.11).
Gros C; Souque A; Schwartz JC
Neuropeptides; 1990 Sep; 17(1):1-5. PubMed ID: 2148814
[TBL] [Abstract][Full Text] [Related]
19. Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide.
Trapani AJ; Smits GJ; McGraw DE; Spear KL; Koepke JP; Olins GM; Blaine EH
J Cardiovasc Pharmacol; 1989 Sep; 14(3):419-24. PubMed ID: 2476621
[TBL] [Abstract][Full Text] [Related]
20. The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
Jardine AG; Connell JM; Northridge D; Dilly SG; Cussans NJ; Davidson G; Doyle J; Leckie BL; Lever AF
Am J Hypertens; 1990 Sep; 3(9):661-7. PubMed ID: 2145871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
